Intellia Therapeutics
NTLA
293 hedge funds and large institutions have $2.6B invested in Intellia Therapeutics in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 124 increasing their positions, 77 reducing their positions, and 36 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 77
33% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 36
4.79% more ownership
Funds ownership: 90.55% → 95.34% (+4.8%)
3% more funds holding
Funds holding: 285 → 293 (+8)
3% more capital invested
Capital invested by funds: $2.53B → $2.6B (+$69M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
30% less call options, than puts
Call options by funds: $21.1M | Put options by funds: $30.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$42.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$28.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$25.6M |
| 4 |
BlackRock
New York
|
+$25.2M |
| 5 |
Two Sigma Investments
New York
|
+$9.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20.4M |
| 2 |
Morgan Stanley
New York
|
-$15.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.81M |
| 4 |
AG
Artal Group
Luxembourg
|
-$8.73M |
| 5 |
Millennium Management
New York
|
-$7.37M |
NTLA Hedge Fund Activity: Q4 2023 in Review
293 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2023, worth a combined $2.6B — up 2.7% from $2.53B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new NTLA positions and 36 closed out — a net gain of 12 holders — while 124 added to existing stakes and 77 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $42.1M. The largest seller was Citadel Advisors, cutting an estimated $20.4M.
- 293 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2023, up from 285 in Q3 2023.
- Funds reported $2.6B of Intellia Therapeutics stock for Q4 2023, up 2.7% quarter-over-quarter.
- 48 funds opened new Intellia Therapeutics positions in Q4 2023 and 36 closed out, a net change of +12 holders.
- The largest Intellia Therapeutics buyer in Q4 2023 was ARK Investment Management, an estimated $42.1M added.
- The largest Intellia Therapeutics seller in Q4 2023 was Citadel Advisors, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2023.